- Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.
- Collaboration agreements for oncology candidates were signed between several major pharmaceutical companies.
- A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.
- Recursion Pharmaceuticals announced strategic alliances with Bayer, Sanofi, Roche, Merck, and Genentech.
A critical strategic collaboration has formed involving Hoffmann-La Roche, Recursion, Recordati, Moderna, Sanofi, and Merck KGaA to diversify pipelines through automated biological research.
1 report, 1 independent
Updated Jul 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A critical strategic collaboration has formed involving Hoffmann-La Roche, Recursion, Recordati, Moderna, Sanofi, and Merck KGaA to diversify pipelines through automated biological research.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Hoffmann-La Roche and Recursion utilized an AI platform to identify novel targets, including an advanced neuroscience target, for early discovery.Sub-event
Six major companies form a critical partnership for research and commercialization.1 source
Keep exploring
The entities involved
-
Hoffmann-La Roche
Swiss healthcare company
-
Recursion (United States)
company in Salt Lake City, United States
-
Sanofi
French pharmaceutical company
-
Merck KGaA
German multinational science and technology company